ArticleOncotarget2017

MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway.

Chunxian Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.